Roquefort Therapeutics (LON:COIL – Get Free Report) released its quarterly earnings data on Monday. The company reported GBX (1.66) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative return on equity of 18.71%.
Roquefort Therapeutics Price Performance
Shares of COIL stock opened at GBX 7.25 on Tuesday. Roquefort Therapeutics has a 12 month low of GBX 6.75 and a 12 month high of GBX 12.50. The company has a market capitalization of £30.94 million, a P/E ratio of -0.33 and a beta of 0.05. The stock has a 50 day moving average of GBX 8.91 and a two-hundred day moving average of GBX 9.31. The company has a current ratio of 0.63, a quick ratio of 3.07 and a debt-to-equity ratio of 8.18.
Insider Buying and Selling at Roquefort Therapeutics
In related news, insider Stephen Paul West bought 261,437 shares of the company’s stock in a transaction dated Monday, September 28th. The stock was acquired at an average cost of GBX 8 per share, with a total value of £20,914.96. Corporate insiders own 36.15% of the company’s stock.
Analyst Ratings Changes
View Our Latest Stock Analysis on COIL
About Roquefort Therapeutics
Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.
Featured Articles
- Five stocks we like better than Roquefort Therapeutics
- Six Flags Launches FlexPay—Is There Any FUN Left in the Stock?
- Brewing Trouble? Starbucks Spills the Beans on 250 Store Closures
- Stitch Fix Stock Plunges as Guidance Puts the Turnaround on Pause
- Harley-Davidson Insiders Are Buying: Is HOG Finally Turning Around?
Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
